May I remind everybody what got us here in the first place.

"Effects of RVX-208 on MACE, ApoA-I and HDLs; a post-hoc analysis from the pooled SUSTAIN and ASSURE clinical trials'"

And as it seems, we will go around the block with more post-hoc analysis in hand from BOM if we can cash up to do just that one more time.

IMO....Koo